CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the safety and tolerability of CS-7017
administered orally twice a day in combination with carboplatin and paclitaxel, and to assess
the pharmacokinetics of CS-7017 in combination with carboplatin and paclitaxel.